Study Summary

Title: Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Authors: Solomon SD, McMurray JJ, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CS, Martinez F et al.
Journal: New England Journal of Medicine
Year: 2022
Publisher: Massachusetts Medical Society
DOI: 10.1056/NEJMoa2206286

2×3 Table

Urgent Visit No Urgent Visit Total
Exposed (Treatment: Dapaglifozin) 60 3071 3131
Unexposed (Control: Placebo) 78 3054 3132

Section 1 — Computation based on Journal

Risk (Exposed): 0.019
Risk (Unexposed): 0.025
Risk Ratio (RR): 0.769
Absolute Risk Reduction (ARR = Ru − Re): 0.006
NNT: 175
NNH (if harm): —

Interpretation: For every 175 treated with Dapaglifozin, you can prevent one Urgent Visit.

Notes: ARR uses Ru − Re. NNT/NNH uses ceil(1/|ARR|). If a denominator is zero, that metric is “—”.

Section 2 — Individualizing Results

Baseline Risk (Control): 0.100
Study RR: 0.769
Estimated Treated Risk: 0.077
Individualized ARR: 0.023

Individualized Interpretation: For every 44 like your patient (baseline risk 0.100) treated with Dapaglifozin, one Urgent Visit may be prevented.

Method: Treated Riskindividual = BaselineRisk × RR; Individualized ARR = BaselineRisk − TreatedRiskindividual.

← New Study View Previous Studies
Delete